YL202 should be intravenously infused — clinical trials using this drug

Public-registry trials using YL202 should be intravenously infused that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.

Trial	Sponsor	Condition	Phase	Sites
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC	MediLink Therapeutics (Suzhou) Co., Ltd.	Locally Advanced or Metastatic Breast Cancer	PHASE2	1

Free site-risk snapshot for any of these trials

Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →